Cat.#: BBM-3C-023
| Description | Porcine Collagen Type I and III, 10 mg from Ace Therapeutics is purified from pig’s tissue. Type I collagen is the most abundant collagen and is found in connective tissues including tendons, ligaments, dermis, and blood vessels. Type III collagen is the second most abundant collagen in tissues and is found most commonly in tissues exhibiting elastic properties such as skin, lungs, intestinal walls, and walls of blood vessels, which resembles other fibrillar collagens in structure and function. |
| Source | Porcine tissue |
| Size | 10 mg/ vial |
| Form | Lyophilized, salt-free |
| Purity | Porcine collagen type I - 45%. Porcine collagen type III - 45%. Porcine collagen type IV - 10%. Porcine collagen type V - below 1%. Non-collagen proteins - below 0.5%. |
| Sterility | Passed sterility test for bacteria and fungi. |
| Storage | Storage (2 years) at -20°C or lower. |
| Shipping | Dry ice |
| Aplications | Used for coating material for cell culture studies. May not be suitable for 3-D gel formation. |
| Cat.# | Name | Description | Price |
|---|---|---|---|
| BBM-3C-039 | Rat Tail Collagen Type I (from Rat Tail Tendon) |
Rat Tail Collagen Type I (from Rat Tail Tendon) from Ace Therapeutics is purified from rat tail by the Birkedal-Hansen method. This product has the advantages of high purity (SDS-PAGE>85%), low endotoxin, and easy storage and transportation, making it convenient for customers to prepare the required concentration.
|
inquiry |
| BBM-3C-043 | Collagen from Human Placenta |
Collagen from Human Placenta is used to induce differentiation of endothelial cells and rat pluripotent cells. This product is a lyophilized powder that can be reconstituted at 1 mg/mL in sterile 0.5 M acetic acid, PBS, or water.
|
inquiry |
| BBM-3C-016 | Bovine Collagen Type VI, Lyophilized, 0.1mg |
Bovine Collagen Type VI, Lyophilized, 0.1mg from Ace Therapeutics is purified from the bovine placenta.
The product is the major collagenous component of microfibrils in elastic fibers and in a larger variety of tissues, which consist of two α-chains of ca.
|
inquiry |
| BBM-3C-045 | Collagen from Human Placenta |
Collagen from Human Placenta is supplied as a 0.5 M acetic acid solution. It can be used to coat tissue culture surfaces to promote cell attachment
|
inquiry |
| BBM-3C-028 | Porcine Collagen Type I, 30 mg |
Porcine Collagen Type I, 30 mg from Ace Therapeutics is purified from porcine tendon.
Type I collagen is found in connective tissues and is the major component of tensile strength of the extracellular matrix (ECM). The product is widely used as a thin layer on tissue-culture surfaces to enhance the attachment and proliferation of a variety of cells including endothelial cells, fibroblasts, hepatocytes, epithelial cells, etc. In addition, the product can self-assemble into a 3-D supramolecular gel in vitro as an ideal biological scaffold.
|
inquiry |
| BBM-3C-037 | Soluble Collagen Type I |
Soluble Collagen TypeⅠ from Ace Therapeutics is purified fromBovine achilles tendon by the Birkedal-Hansen method.
|
inquiry |
| BBM-3C-042 | Collagen Type IV (Human Placenta) |
Collagen Type IV (Human Placenta) from Human Cell Culture from Ace Therapeutics is derived from human placenta and is highly purified native, type IV collagen.
|
inquiry |
| BBM-3C-069 | Rat Collagen I |
Rat Collagen I from Ace Therapeutics is a high concentration matrix extracellular matrix protein purified from rat tail tendon. This product is capable of polymerizing to form hydrogels and is a purified matrix ECM protein specifically designed and developed for 3D culture.
|
inquiry |
| BBM-3C-056 | Porcine Gelatine |
Porcine Gelatine from Ace Therapeutics is a purified gelatin matrix from porcine tissue. The product can enhance the adsorption of various normal cells and transfected cells.
|
inquiry |
| BBM-3C-034 | Human Collagen Type IV, 0.1mg |
Human Collagen Type IV, 0.1mg from Ace Therapeutics is purified from human cartilage.
|
inquiry |
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.